• Home
  • NEW DAY MEDICINE
  • 4(32)2020
  • 86 -4 (32/2) 2020 — Zaxirova N.N., Mamatova M.R. — CLINICAL AND PATHOLOGICAL FEATURES AND PREVALENCE OF GESTATIONAL TROPHOBLASTIC DISEASE

86 -4 (32/2) 2020 — Zaxirova N.N., Mamatova M.R. — CLINICAL AND PATHOLOGICAL FEATURES AND PREVALENCE OF GESTATIONAL TROPHOBLASTIC DISEASE

CLINICAL AND PATHOLOGICAL FEATURES AND PREVALENCE OF GESTATIONAL
TROPHOBLASTIC DISEASE

Zaxirova N.N. -Andijan State Medical Institute

Mamatova M.R. -Andijan State Medical Institute

Nadjmitdinova D.A. -Andijan State Medical Institute

Resume

Gestational trophoblastic disease (GTD) is a term that unites a group of pathological conditions associated with pregnancy that develop as a result of abnormal cell proliferation of the trophoblast after fertilization. The aim of the research was to study the clinical and pathological features and the prevalence of various forms of GTD in Uzbekistan. As a result of the research, the following conclusions were made: there is a tendency to increase the incidence of GTD. A strict research of the incidence and comprehensive examination is necessary for the timely identification of patients with malignant trophoblastic tumors.

Key words: gestational trophoblastic disease, hydatidiform mole, choriocarcinoma.

First page

353

Last page

357

For citation: Zaxirova N.N., Mamatova M.R., Nadjmitdinova D.A., Clinical and pathological features and prevalence of gestational trophoblastic disease//new day in Medicine 4(32)2020 353-357

List of References

  1. Акушерство. Национальное руководство. М. 2011; С.930-941
  2. Быстрицкая Д.А. Тихоновская М.Н. Мещерякова Л.А., Кузнецов В.В. Давыдова И.Ю. Трофобластические опухоли: к вопросу о классификации (часть I). // Российский отологи­ческий журнал. № 1. 2014. С.54-56
  3. Быстрицкая Д.А. Тихоновская М.Н. Мещерякова Л.А. Кузнецов В.В. Давыдова И.Ю. Трофобластические опухоли: к вопросу о классификации и факторах иропюза (часть II). // Российский отологический журнал. № 2. 2014. С. 32-36
  4. Мамарасулова Д.З. Маматова М.Р. Пузыртгй занос: совре­менный взгляд на факторы риска и новые пути профилакти­ки. /’/’Новый дет в медицине. 2 (26) 2019. С. 30-33.
  5. Banach P… Suchy W… Derezi? nski P.. Matysiak J… Kokot Z.J… Nowak-Markwitz E. Mass spectrometry as a tool for biomarkers searching in gynecological oncology. //Biomed. Pharmacother. 2017. 92. Р. 836-842.
  6. Boufettal H. Coullin P. Mahdaoui S. Noun M. Hermas S. Samouh N. [Complete hydatiforme mole in Morocco: epidemiological and clinical study]. //J Gynecol Obstet Biol Reprod (Paris) 2011; 40: Р.419-29; PMID:21458172;
  7. Jean-Jacques Candelier. The hydatidiform mole. // Cell adhesion & migration. 2016. vol. 10. nos. 1-2. Р. 226-235.
  8. Hasanzadeh M.. Sharifi N.. Esmaieli H. et al. Immuno­histochemical expression of the proliferative marker Ki67 in hydatidiformmoles and its diagnostic value in the progression to gestational trophoblastic neoplasia. //J Obstet Gynaecol Res 2013;39(2):Р. 572-7
  9. Kohorn E.I. (2007) Dynamic staging and risk factor scoring for gestational trophoblastic disease. Int. J. Gynecol. Cancer., 17 (5): 1124-1130.
  10. Kubelka-Sabit KB, ProdanovaI, Jasar D, Bozinovski G, Filipovski V, Drakulevski S, Plaseska-Karanfilska D. Molecular and Immunohistochemical Characteristics of Complete Hydatidiform Moles.// Balkan J. Med. Genet. -2017- Jun 30; 20(1). P. 27-34.
  11. Landolsi H, Missaoui N, Brahem S, Hmissa S, Gribaa M, Yacoubi MT. The usefulness of p57(KIP2) immunohistochemical staining and genotyping test in the diagnosis of the hydatidiform mole. / /Pathol Res Pract. 2011;207(8):P. 498-504.
  12. Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. / /Am J Obstet Gynecol 2010; 203:531-9;
  13. Mittal P., Klingler-Hoffmann M., Arentz G., Zhang, C., Kaur, G., Oehler M.K., Hoffmann P. Proteomics of endometrial cancer diagnosis, treatment, and prognosis. //Proteom. Clin. Appl. 2015, P. 217-229.
  14. Paulina Banach, Pawe? Derezi?nski, Eliza Matuszewska, Jan Matysiak, Hubert Bochy?nski, Zenon J. Kokot and Ewa Nowak- Markwitz. MALDI-TOF-MS Analysis in the Identification of Proteomic Patterns of Gestational Trophoblastic Disease. // Metabolites 2019, 9, 30. P. 345-350.
  15. Seckl M.J., SebireN.J., Fisher R.A. et al. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. – 2013. – Vol. 24 (Suppl. 6). – P. 39-50.
  16. Shi, Z.H.; Zhao, C.; Wu, H.; Wang, W.; Liu, X.M. CLIC1 protein: A candidate prognostic biomarker for malignant- transformed hydatidiformmoles. // Int. J. Gynecol. Cancer 2011, 21, P. 153-160.
  17. Stevens F.T., Katzorke N., Tempfer C., Kreimer U., Bizjak G.I., Fleisch M.C., Fehm T.N. Gestational Trophoblastic Disorders: An Update in 2015. //Geburtshilfe Frauenheilkd 2015, 75, P.1043-1050.
  18. Shih, I. Trophoblastic vasculogenic mimicry in gestational choriocarcinoma. Mod Pathol 24, 646-652 (2011). https://doi.org/ 10.1038/modpathol.2010.231
  19. Ch.Lok, N.Trommel, L.Massuger, F.Golfier, M.Seckl. Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease \\ European Journal of Cancer Volume 130, May 2020, Pages 228-240
  20. K.E.Earp, B.W.Hancock, D.Short, R.A.Harvey, R.A.Fisher, D.Drew, N.Sarwar, J.A.Tidy, M.C.Winter, P.Chien, M.J.Seckl. Do we need post-pregnancy screening with human chorionic gonadotrophin after previous hydatidiform mole to identify patients with recurrent gestational trophoblastic disease? \\ European Journal of Obstetrics & Gynecology and Reproductive Biology Volume 234, March 2019, Pages 117-119

file

download